


World Journal of *Gastrointestinal Pathophysiology*

World J Gastrointest Pathophysiol 2020 December 12; 11(6): 114-130



REVIEW

- 114 Clinical relevance of intestinal barrier dysfunction in common gastrointestinal diseases

Muehler A, Slizgi JR, Kohlhof H, Groeppel M, Peelen E, Vitt D

ABOUT COVER

Editorial board member of *World Journal of Gastrointestinal Pathophysiology*, Dr. Francisco Bosques-Padilla is a Professor at the School of Medicine, Universidad Autónoma de Nuevo Leon (UANL), in Monterrey, Mexico. He undertook his postgraduate training at the Hospital Universitario J.E. Gonzalez, where he completed a fellowship in Internal Medicine and Gastroenterology in 1987. He then continued his training as a Hepatology Research Fellow at the Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubiran until 1990, and obtained his PhD from the UANL in 1999. His ongoing research interests involve the relationship between *Helicobacter pylori*, peptic ulcers, and gastric cancer, as well as the epidemiology and treatment of inflammatory bowel disease, hepatic encephalopathy and microbiota imbalance in alcoholic liver disease. Currently, Dr. Bosques serves as Director of the Digestive Health Institute at the Zambrano Hellion Hospital Tecsalud in Monterrey, Mexico. (L-Editor: Filipodia)

AIMS AND SCOPE

The primary aim of the *World Journal of Gastrointestinal Pathophysiology* (WJGP, *World J Gastrointest Pathophysiol*) is to provide scholars and readers from various fields of gastrointestinal pathophysiology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGP mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal pathophysiology and covering a wide range of topics including disorders of the esophagus, stomach and duodenum, small intestines, pancreas, biliary system, and liver.

INDEXING/ABSTRACTING

The WJGP is now abstracted and indexed in Emerging Sources Citation Index (Web of Science), PubMed, PubMed Central, China National Knowledge Infrastructure (CNKI), and Superstar Journals Database.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Jia-Hui Li; Production Department Director: Yun-Xiaojuan Wu; Editorial Office Director: Jia-Ping Yan.

NAME OF JOURNAL

World Journal of Gastrointestinal Pathophysiology

ISSN

ISSN 2150-5330 (online)

LAUNCH DATE

April 15, 2010

FREQUENCY

Continuous Publication

EDITORS-IN-CHIEF

Kusum K Kharbanda, Tsutomu Nishida, Somchai Amorniyotin

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2150-5330/editorialboard.htm>

PUBLICATION DATE

December 12, 2020

COPYRIGHT

© 2020 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Clinical relevance of intestinal barrier dysfunction in common gastrointestinal diseases

Andreas Muehler, Jason R Slizgi, Hella Kohlhof, Manfred Groeppel, Evelyn Peelen, Daniel Vitt

ORCID number: Andreas Muehler 0000-0001-5811-5976; Jason R Slizgi 0000-0001-8870-3138; Hella Kohlhof 0000-0001-8279-5203; Manfred Groeppel 0000-0002-6105-4083; Evelyn Peelen 0000-0002-9332-1801; Daniel Vitt 0000-0003-4741-0317.

Author contributions: Muehler A, Slizgi JR, Kohlhof H, Groeppel M, Peelen E, and Vitt D reviewed and evaluated the literature for inclusion in the review in different therapeutic areas; Muehler A and Slizgi JR prepared the initial draft of the manuscript; Muehler A, Slizgi JR, Kohlhof H, Groeppel M, Peelen E and Vitt D reviewed, edited and approved the final version of the manuscript.

Conflict-of-interest statement: Dr. Muehler and other co-authors report a relationship with Immunic AG (stock, stock options, employment), with drug development projects relevant to this work. In addition, Immunic AG has licensed patent WO 2008/138943 A2 which is part of the development projects in the area of gastrointestinal diseases. Other authors have no conflicts of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in

Andreas Muehler, Jason R Slizgi, Hella Kohlhof, Manfred Groeppel, Evelyn Peelen, Daniel Vitt, Immunic, AG, Gräfelting 82166, Germany

Corresponding author: Andreas Muehler, MD, Chief Medical Officer, Immunic, AG, Lochhamer Schlag 21, Gräfelting 82166, Germany. andreas.muehler@imux.com

Abstract

The intestinal barrier is a complex and well-controlled physiological construct designed to separate luminal contents from the bowel wall. In this review, we focus on the intestinal barrier's relationship with the host's immune system interaction and the external environment, specifically the microbiome. The bowel allows the host to obtain nutrients vital to survival while protecting itself from harmful pathogens, luminal antigens, or other pro-inflammatory factors. Control over barrier function and the luminal milieu is maintained at the biochemical, cellular, and immunological level. However, disruption to this highly regulated environment can cause disease. Recent advances to the field have progressed the mechanistic understanding of compromised intestinal barrier function in the context of gastrointestinal pathology. There are numerous examples where bowel barrier dysfunction and the resulting interaction between the microbiome and the immune system has disease-triggering consequences. The purpose of this review is to summarize the clinical relevance of intestinal barrier dysfunction in common gastrointestinal and related diseases. This may help highlight the importance of restoring barrier function as a therapeutic mechanism of action in gastrointestinal pathology.

Key Words: Intestinal barrier; Microbiome; Gastrointestinal disease; Inflammatory bowel disease; Inflammatory bowel syndrome; Colitis

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Intestinal barrier dysfunction is an underlying pathophysiological feature in many gastrointestinal diseases. Understanding barrier dysfunction may help drive a deeper understanding of gastrointestinal pathology and identify novel way(s) to manage and/or treat disease. Here, we summarize the evidence supporting intestinal barrier dysfunction in common immune-mediated gastrointestinal diseases and its

accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Invited manuscript

Specialty type: Gastroenterology and hepatology

Country/Territory of origin: Germany

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): B, B
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0

Received: July 21, 2020

Peer-review started: July 21, 2020

First decision: September 24, 2020

Revised: October 7, 2020

Accepted: October 26, 2020

Article in press: October 26, 2020

Published online: December 12, 2020

P-Reviewer: Fujimori S, Velikova TV

S-Editor: Fan JR

L-Editor: A

P-Editor: Li JH



clinical relevance.

Citation: Muehler A, Slizgi JR, Kohlhof H, Groeppel M, Peelen E, Vitt D. Clinical relevance of intestinal barrier dysfunction in common gastrointestinal diseases. *World J Gastrointest Pathophysiol* 2020; 11(6): 114-130

URL: <https://www.wjgnet.com/2150-5330/full/v11/i6/114.htm>

DOI: <https://dx.doi.org/10.4291/wjgp.v11.i6.114>

INTRODUCTION

The gut contains about 0.2 kg, or approximately 40 trillion cells, of bacteria (commonly referred to as the microbiome) and maintains a highly specialized architecture to manage the host's interaction with food-borne and bacterial antigens^[1]. While the epithelial monolayer and multiprotein junctional complexes [*e.g.*, tight junctions (TJs)] comprise the primary physical barrier, other cell types, such as mucin-producing Goblet cells and Paneth cells, have antimicrobial functions^[2,3]. The bowel's defense system is further supported by proximal lymphoid tissue, which is critical to maintaining homeostasis with respect to microorganisms beneficial to the host as well as responding to pathogenic invaders. This interconnected system facilitates a robust immune response and allows broad coverage over a large surface area. In fact, it is estimated that the intestinal lining contains more immune cells and produces more antibodies than any other organ^[4].

Barrier maintenance is challenged by the rapid turnover of intestinal epithelial cells—occurring every 4-5 d^[5]. Homeostasis is readily maintained, in part, due to cell shedding and stem cell proliferation within the intestinal crypts; however, loss of intestinal barrier function may expose antigens of the microbiome to immune cells inside luminal epithelium. This can activate an immune response and cause pathology. The purpose of this review is to characterize and quantify the clinical relevance of impaired intestinal barrier function in common gastrointestinal diseases. Specifically, we will review Crohn's disease (CD), ulcerative colitis (UC), diarrhea-predominant irritable bowel syndrome (IBS-D), and an emerging pharmacotherapy-associated condition known as immune checkpoint inhibitor-related colitis. In addition to reviewing the current state of knowledge, this review may help identify knowledge gaps in the understanding of impaired intestinal barrier function and highlight the relevance of restoring barrier function as a therapeutic mechanism of action.

CLINICAL ASSESSMENT OF BOWEL PERMEABILITY

Functional *in vivo* assessment of bowel permeability relies on the measurement of orally administered sugars, or some other indigestible probe, that reflects non-mediated absorption through the paracellular and/or transcellular route. Selection of an appropriate test probe involves knowledge of the molecules' properties, route(s) of permeation, and potential confounding variables—which have been described elsewhere^[6]. A summary of clinically available probes is listed in [Table 1](#).

Lactulose/mannitol


The lactulose/mannitol (L/M) test is the most widely used method to evaluate small intestinal permeability *in vivo*. The basis for a two-sugar test relies on the para- and transcellular absorption pathways of lactulose and mannitol. Mannitol is a monosaccharide approximately 6.5 Å in molecular diameter and is readily absorbed by passive diffusion through the membrane of bowel epithelium (transcellular transport). In contrast, the larger disaccharide lactulose (9.5 Å) is minimally absorbed because of its size; however in abnormal situations (*e.g.* pathology) lactulose can fit through intercellular spaces and becomes absorbed *via* the paracellular route ([Figure 1](#))^[7-9]. Following absorption into the blood stream, both sugars are then renally secreted by glomerular filtration without active re-absorption and are thus readily measurable in blood and urine. Because of the paracellular *vs* transcellular absorption pattern of lactulose and mannitol, the L/M ratio is small (or close to zero) under normal physiological conditions. In disease, alterations to lactulose and/or mannitol excretion

Table 1 Functional probes used to clinically assess bowel permeability in humans

Functional probe	Proposed test site	Sample site	Ref.
⁵¹ Cr-EDTA	Whole intestine	Urine	Bjarnason <i>et al</i> ^[14] , 1983
Lactulose/mannitol ¹	Small intestine	Plasma/urine	Rao <i>et al</i> ^[11] , 2011
PEG400	Whole intestine	Urine	Ma <i>et al</i> ^[132] , 1990
Sucralose ²	Colon	Urine	Anderson <i>et al</i> ^[133] , 2004
Sucrose ²	Gastroduodenal	Urine	Meddings <i>et al</i> ^[134] , 1993

¹Cellobiose and L-rhamnose have been used as alternatives to lactulose and mannitol, respectively.

²Usually in combination with lactulose/mannitol. ⁵¹Cr-EDTA: Chromium-51-ethylenediaminetetra-acetate.

**Figure 1 Absorption pathways of lactulose and mannitol.**

are thought to reflect pathological features of leakiness (lactulose) normalized to surface area (mannitol)^[10]. Hence, the L/M ratio is higher under pathological conditions due to increased paracellular absorption of lactulose. Both sugars cannot be metabolized by bacteria in the small bowel (but are by colonic bacteria) and are unaffected by differences in liver metabolism, which ensure its integrity is maintained for measurement^[6]. The L/M test consists of concomitant oral administration of lactulose and mannitol (dissolved in water) followed by timed blood or urine collection (up to 24 h). Urinary excretion from 0 to approximately 5 h reflects small intestine permeability, although methodological enhancements of the L/M tests suggest that shorter time frames (*e.g.*, 0–2 h) may be ideal^[11]. L/M can also be measured in serum to reduce complications of timed urine collections. For example, one dual sugar test was shown to have similar results when analyzing either serum or urine^[12]. The serum-based test was simpler because it required less sample volume, needed a short waiting time after sugar ingestion (1 h compared to 5 h for urine collection), and was more cost-effective to analyze than urine^[12]. The L/M test has also shown intra-individual and analytical repeatability, making it a simple and reliable measurement method^[13].

The primary results of the test are expressed as lactulose-to-mannitol ratio (*e.g.* lymphocyte-to-monocyte ratio (LMR) in urine: %lactulose/%mannitol where “%” represents the percentage of the ingested dose) with a higher LMR indicating increased small intestine permeability. Other sugars have been investigated (*e.g.* L-arabinose, L-rhamnose, raffinose) but there appears to be no widely-accepted practical benefit over L/M^[6].

Chromium-51-ethylenediaminetetra-acetate

Chromium-51-ethylenediaminetetra-acetate (⁵¹Cr-EDTA) is a radiolabeled form of the

indigestible EDTA. ^{51}Cr -EDTA is orally administered and transverses the lumen paracellularly, similar to large sugars, where it is readily excreted in urine^[14]. ^{51}Cr -EDTA is believed to cross both the small and large intestine, in contrast to lactulose and mannitol, which predominately transverses the small intestine only^[15]. Moreover, when combined with a sugar probe to correct for small intestinal absorption, ^{51}Cr -EDTA allows assessment of colonic permeability because it is not metabolized by the microbiome of the colon. Routine usefulness of the test, however, appears to be limited by reliability and practicality (*e.g.*, up to 24 h urine collection, requires gamma counter, short shelf-life of ^{51}Cr)^[6,14].

Confocal laser endomicroscopy

Confocal laser endomicroscopy is an *in vivo* real-time imaging method that can detect and quantify mucosal abnormalities at the microscopic level following administration of a contrast agent. It has several clinical applications such as in the identification of dysplasias/neoplasias, diagnostic work-up of Inflammatory bowel disease (IBD), and other surgical use cases. Confocal laser endomicroscopy has been also experimentally applied to assess intestinal permeability^[16,17]. The main advantage is that it can quantify permeability at specific intestinal site(s), which may be cross-referenced with histological or endoscopic findings. However, the technique remains experimental and there appears to be no well-validated methodology or robust reproducible findings in the literature^[18]. Technical and analytical challenges may have also contributed to its lack of wide spread acceptance.

IBD

IBD is a group of chronic gastrointestinal disorders primarily consisting of CD and UC. Genetic susceptibility and environmental triggers underly the etiology of pathology which converge to activate an immune response associated with compromised intestinal barrier^[19-21]. For example, nucleotide-binding oligomerization domain 2 (NOD2), expressed in ileal Paneth cells, is induced in response to the presence of bacterial components and activates an innate immune response; genetic analysis has confirmed the relationship between mutations in NOD2 and CD and it is estimated that 30%-50% of CD patients in the Western hemisphere harbor one mutant allele of NOD2^[22-24]. Two pathogenic alleles increases the risk of CD by 20-40 times^[23,24]. These data suggest that certain susceptibility factors may contribute to dysfunctional/overactive innate and adaptive immune pathways that may not be able to self-regulate as it would under normal or homeostatic conditions. Substantial data implicate abnormal bowel barrier function as an underlying pathological feature of IBD.

CD

CD is a chronic relapsing-remitting inflammatory disease of the gastrointestinal tract, the cause of which remains generally unknown. The disease affects the gastrointestinal tract discontinuously from mouth to anus, but most commonly the disease is located both in ileum and colon (40%), followed by a disease in the small bowel only (30%), and in the colon only (25%). CD can lead to severe disability and significant reduction in quality of life^[25,26]. Abnormal intestinal barrier function has been a well-established pathological feature of CD for nearly 40 years^[27-31]. Impaired intestinal function may be multifactorial but structural barrier damage appears to be an characteristic pathological feature (Table 2).

The intestinal barrier, as it relates to bowel epithelial function, consists of a polarized monolayer of epithelial columnar cells connected by TJs, an intercellular feature designed to create separation between gut and lumen. Four groups of proteins comprise TJs: Occludin tricellulin, junctional adhesion molecule, and claudins^[32-35]; The latter appear to have a particular crucial role in barrier function including seal or pore-forming properties and may act as paracellular channels for small ions^[36-39]. The relevance of TJ abnormalities in CD has been demonstrated in sigmoid colon biopsies, which revealed a reduction in the number of TJ strands, reduced depth of TJ meshwork, and strand breaks^[40]. Expression of sealing claudin-3, -5 and -8 and occludin were diminished, indicating altered TJ structure^[40-42]. The pore-forming claudin 2 also appears to be upregulated^[40,43]. These data were generated from patients with mild-to-moderate CD, suggesting that impaired TJ structure may characteristic that occurs early in disease progression. This is consistent with the hypothesis that permeability abnormalities are a primary disorder, as evidenced by healthy first-

Table 2 Clinical intestinal permeability function in gastrointestinal diseases

Disease	Disease activity	Functional probe	Intestinal permeability change	Ref.
CD	Not reported	C/M	↑	Secondulfo <i>et al</i> ^[135] , 2001
	Not reported	⁵¹ Cr-EDTA	↑	Jenkins <i>et al</i> ^[136] , 1987
	Low activity and high activity	Iohexol	Low activity: ↑; high activity: ↑	Gerova <i>et al</i> ^[55] , 2011
	Low activity and high activity	L/M	Low activity: ↑; high activity: ↑	Benjamin <i>et al</i> ^[57] , 2008
	Remission, low activity, and high activity	L/M	Remission: ↔; low activity: ↑; high activity: ↑	Welcker <i>et al</i> ^[82] , 2004
	Remission	L/M	↑	Wyatt <i>et al</i> ^[52] , 1993
	Low activity	L/M; L/R; R/M	L/M: ↑; L/R: ↑; R/M: ↔	Katz <i>et al</i> ^[30] , 1989
	Low activity	L/M; L/R; L/PEG; PEG/M; PEG/R	↔	Munkholm <i>et al</i> ^[45] , 1994
UC	Not reported	⁵¹ Cr-EDTA	↑	Jenkins <i>et al</i> ^[136] , 1987
	Remission, low activity, and high activity	C/M; C/R; L/M; L/R;	Remission: ↔ or ↑ ¹ ; low activity: ↔ or ↑ ¹ ; high activity: ↑	Welcker <i>et al</i> ^[82] , 2004
	Low activity and high activity	Iohexol	Low activity: ↑; high activity: ↑	Gerova <i>et al</i> ^[55] , 2011
	Remission	L/M; S; Su	↑	Büning <i>et al</i> ^[83] , 2012
	Remission	L/M/S/Su/E/R	↔ ²	Wegh <i>et al</i> ^[81] , 2019
IBS-D	Active	⁵¹ Cr-EDTA	↑	Gecse <i>et al</i> ^[103] , 2012
		⁵¹ Cr-EDTA	↑	Dunlop <i>et al</i> ^[102] , 2006
		L/R	↑	Mujagic <i>et al</i> ^[105] , 2014
		L/M	↑	Shulman <i>et al</i> ^[98] , 2014
		L/M	↑	Vazquez-Roque <i>et al</i> ^[100] , 2012
		L/M	↑	Zhou <i>et al</i> ^[104] , 2009
		L/R	↑	Zhou <i>et al</i> ^[137] , 2010

¹Increased or no change depending on the functional test.

²Study did not include a true (healthy) control arm. ⁵¹Cr-EDTA: Chromium-51-ethylenediaminetetra-acetate; C: Cellobiose; CD: Crohn's disease; E: Erythritol; IBS-D: Diarrhea-predominant irritable bowel syndrome; L: Lactulose; M: Mannitol; PEG: PEG400; R: L-rhamnose; S: Sucrose; Su: Sucralose; UC: Ulcerative colitis; ↑: Increase; ↔: No change.

degree relatives of CD patients who display detectable permeability defects and who also have a higher risk of developing CD compared to healthy non-relatives^[44-47]. Zeissig *et al*^[40] (2007) also discovered that epithelial apoptosis was increased in mild-to-moderate CD, a feature previously thought to be specific to UC^[40]. These data implicate that both changes to TJ structure and epithelial apoptosis may serve as a mechanistic explanation(s) consistent with barrier dysfunction. This hypothesis is also consistent with less pronounced changes to TJ structure and epithelial apoptosis in patients in remission, suggesting that epithelial structure may correlate with clinical symptoms, although permeability alterations have been observed in areas evident of lesions in addition to areas absent of macroscopic injury^[48,49].

Increased intestinal permeability in patients with CD is well-recognized and has also been shown to associate with symptomatic status in patients with IBD. In one prospective study, patients with symptomatic IBD had a significantly higher median Confocal Leak Score (CLS) (19.0) than patients with asymptomatic IBD (7.3; $P < 0.001$) or control subjects (5.9, $P < 0.001$)^[50]; no differences in CLS were found between control subjects and asymptomatic IBD patients, suggesting that low barrier function may be a causative mechanism underlying IBD symptoms. This was confirmed on a symptom level when regression analysis revealed that every increase in CLS of 1.9 correlated with an additional diarrheal motion per day^[50]. Other studies have found a relationship between increased intestinal permeability in clinically inactive patients and also demonstrated a correlation with pending disease relapse^[51,52]. Wyatt *et al*^[52] (1993) prospectively followed 72 CD patients in symptomatic remission and following

a L/M test, discovered the permeability index (PI) was significantly higher in patients than in controls at baseline (0.046 *vs* 0.018, respectively)^[52]. After one year, the relapse rate was 70% in CD patients who had an abnormal PI compared to 17% of patients who had a normal PI. The sensitivity of the PI as predictor of relapse was 81% and specificity was 73%. Other studies are consistent with these findings and have estimated relative risk of relapse within 1 or 2 years in patients with elevated intestinal permeability to be approximately 3-18^[7,17,51,53]. This may be explained, in part, by the association between increased intestinal permeability, inflammation, and disease activity (*i.e.* Crohn's disease activity index)^[54,55]. In addition, increased epithelial gaps as measured by confocal laser endomicroscopy appear to predict hospitalization or surgery in patients with IBD^[56]. These data point to elevated bowel permeability that may allow for a greater probability of interaction between certain pathogens of the microbiome with the epithelial immune system of the bowel.

Elevated intestinal permeability may also indicate greater disease involvement. For example, more patients with ileo-colonic disease (57.8%) had an abnormal PI as measured by L/M compared to 26.7% and 15.6% of patients with colonic and small intestinal disease, respectively^[57]. The authors also found that patients with stricturing disease had a significantly elevated LMR compared to patients with non-fistulizing non-stricturing disease. These data highlight the clinical relevance of intestinal permeability measures in the context of disease involvement, symptoms of the IBD disease, and as trigger for relapse that may suggest restoring barrier function may be a useful approach to maintain remission^[7,52,53,58,59]. It should be noted that not all studies have found intestinal permeability abnormalities in CD^[45]. Although the reasons for this observation are not clear, differences in study design, study population, selected probe, sample size, and analytical methods, among others, may contribute to conflicting literature reports.

As noted earlier, increased intestinal permeability may or may not occur in the presence of histological findings. Protein antigen uptake in macroscopically normal segments of distal ileum of patients with CD was reported to be increased despite being histologically unaffected^[60]. Early histological lesions appear to occur in the follicle-associated epithelium (FAE) of lymphoid follicles and Payer's Patches located in the mucosa, which can occur even in the presence of normal overlying epithelium^[61,62]. Indeed, Keita *et al*^[63] (2008) discovered enhanced intercellular and transcellular uptake of *E. Coli* across FAE in ileal CD, but not UC, indicating defective barrier function at immunological inductive sites^[63]. This appears to be related to microtubule-, microfilament-dependent internalization and transcytosis of bacteria associated with enterocyte cytoskeletal changes under conditions of stress—further linking structural changes to increased permeability^[64]. *In vivo* studies support bacterial translocation secondary to increased paracellular permeability as the mechanistic basis for chronicity and/or acute relapses in IBD^[65]. These examples may help explain the relevance of barrier function and associated functional tests in the absence of endoscopic and/or histological findings.

Most available treatments in CD aim to control symptoms (*e.g.*, thiopurines, and steroids) or reduce the immune response, for example by inhibiting tumor necrosis factor- α (TNF- α) (*e.g.* infliximab, adalimumab, golimumab, and certolizumab pegol)^[66]. Although anti-TNF- α agents have proven clinically beneficial, approximately 1 in 3 do not respond to induction therapy, and of those who do respond, approximately 1 in 3 become secondary non-responders during maintenance therapy^[67-71]. Anti-TNF- α agents are also associated with several side effects (*e.g.* risk of infection, malignancies, skin lesions, immune reactions, peri-operative complications, and decreased fertility)^[72-75]. Persistent diarrhea in patients with CD despite mucosal healing (Mayo scores of 0-1 or segmental endoscopic severity CD scores of 0-5) is not uncommon suggesting that achieving mucosal healing alone through conventional management may be insufficient in some patients. This may warrant developing therapies targeted to intestinal barrier dysfunction and dysbiosis^[76]. We suggest that next generation treatments for CD should focus on restoring bowel barrier function as a way to induce and maintain remission which may also prevent some of the side effects of long-term general immunosuppressive therapy.

UC

Similar to CD, the pathogenesis of UC appears to be related to both genetic and environmental susceptibility factors. UC differs in that it continuously affects the colon and perirectal region with shallow and indiscrete ulcers associated with inflammation limited to the mucosa. Structural characterization of the epithelia in UC appears less robust compared to the available evidence available in CD; however, some notable defects have been reported. Freeze-fracture electron microscopy revealed epithelial cell

TJ strand count was reduced by approximately 30% in UC biopsies compared to controls^[77]. This paralleled the authors findings that found a 50% and 80% reduction in total and epithelial wall resistance, respectively, using alternating current impedance analysis, which indicates a leak-flux imbalance that may help explain diarrhea in UC^[77]. Similar studies corroborate these reports and also suggest that apoptotic foci are a source of epithelial leaks that appear more pronounced with increasing inflammation^[78]. Indeed, Th2 cytokines, *e.g.*, interleukin (IL)-13, have been shown to be important effector molecules relevant to epithelial dysfunction that affect tight junctions and cellular apoptosis^[79]. Cytokine-mediated altered expression of TJs appears to occur at the signal transduction level^[80].

In contrast to CD, patients with UC and in remission generally do not always appear to have notable permeability defects (Table 2). Wegh *et al*^[81] (2019) reported that when using a 5-sugar test, intestinal permeability in patients with UC in clinical remission was not different compared to historic values (*e.g.*, lactulose/rhamnose approximately 0.02-0.06), although the study did not include a true control arm^[81]. Urinary sucrose excretion and sucralose/erythritol ratio also appeared normal. This was consistent with normal or slightly abnormal inflammatory markers in the study population, suggesting that functional permeability tests may have little relevance in subclinical disease particularly in the absence of abnormal biomarkers. Similar findings were observed by Welcker *et al*^[82] (2004) when using multiple functional probes^[82]. In a larger study including patients with UC in remission and healthy first degree relatives however, an elevated LMR was observed significantly more often in UC patients in remission (28.1%) compared with healthy controls (6.1%; $P < 0.001$)^[83]. This is somewhat paradoxical as UC affects the colon, and gastroduodenal and colonic permeability were found to be normal using sucrose and sucralose as functional markers, respectively. However, healthy first degree relatives also had an higher prevalence of elevated LMR compared to controls (20% *vs* 6.1%, respectively, $P = 0.01$), possibly indicating that abnormal permeability may be a risk factor rather than a reliable marker of disease, at least in patients in remission^[83].

Despite histological and *in vitro* evidence indicating colonic barrier abnormalities, clinical data that reliably demonstrate altered barrier function in active UC appears less clear compared to CD. This may be related to the observation that intestinal permeability is in UC less prevalent than in CD^[55]. Welcker *et al*^[82] (2004) for example reported increased permeability in patients with low and high activity UC^[82]. However, the interpretation of this evidence is potentially limited by the use of multiple functional tests (multiplicity) and low sample size (*e.g.*, $n = 4$ in patients with highly active UC). Further research is needed to clarify the magnitude, clinical relevance, and true anatomical location(s) of impaired barrier function, particularly in active UC.

The therapeutic goals of UC are similar to CD: Induce and maintain remission. Biologic agents including anti-TNF- α agents, Janus kinase inhibitors, IL-12/IL-23 inhibitors, and integrin receptor antagonists are considered when conventional therapies (*e.g.* aminosalicylates, oral immunomodulators, and corticosteroids) are inadequate. Because these agents are immune-targeting, they carry traditional down side risks of potentially long-term immunosuppression and can have notable contraindications (*e.g.* in patients with advanced heart failure or neurological conditions)^[84].

IBS

IBS is primarily characterized by recurring abdominal pain and bowel movement changes without discernable gross pathology^[85]. Patients experience mixed symptoms such as pain, bloating, abnormal stools, and dyspepsia and are categorized by stool pattern: Diarrhea predominant (IBS-D), constipation predominant (IBS-C), or mixed (IBS-M). IBS is highly prevalent (global prevalence: Approximately 10%) and negatively affects quality of life, work productivity, and can even cause severe disability^[86-88].

The pathophysiology of IBS appears multifactorial. Historically, environmental and psychosocial triggers, genetic modifiers, intestinal dysmotility, microbiota disturbances, and bile acid malabsorption, among others, had been proposed^[89-93]. However, more recently IBS is thought to be a disease of the gut-brain axis with the trigger being an interaction between the microbiome and certain immune cells^[94]. Mast cells, for example, have been shown to correlate with intestinal permeability in patients with IBS-D and are a key mediator of downstream inflammation that are also

linked to symptoms such as pain^[95,96]. Emerging evidence continues to support mast cells as central to the initiation and symptomatic presentation of IBS.

Gastroenteritis (especially related to *Campylobacter jejuni* infection) has been shown to precede or cause IBS symptoms, particularly in IBS-D, suggesting that alterations to the intestinal milieu and subsequent immune stimulation may be a primary driver contributing to IBS-D pathology^[91,97]. Spiller *et al*^[97] (2000) was among the first to report increased gut permeability (approximately 4-fold increase in LMR compared to controls) in a small cohort of patients with post-dysenteric IBS^[97]; immunohistology also revealed elevated CD3, CD4, and CD8 lymphocyte counts in the lamina propria, consistent with the known relationship between the immune system and gut permeability. Subsequent studies have confirmed these observations^[91,98-100]. Thus, impaired intestinal barrier function and subsequent microbial infiltration have become central to the proposed gut disease model in certain forms of IBS^[101]. The pathogenesis of IBS also appears to link a relationship between the microbiome, gut, and brain, as neural networks have been shown to be influenced by the composition of the gut microbiome^[94]; therefore the gut-brain axis is highly relevant in the pathophysiology of IBS.

IBS-D

Increased intestinal permeability appears greatest in IBS-D. Dunlop *et al*^[102] (2006) showed that proximal small intestinal permeability, as measured by ⁵¹Cr-EDTA, was significantly higher in patients with postinfectious IBS-D compared to patients with IBS-C and healthy control subjects^[102]. Patients with IBS-D but without a history of acute gastroenteritis had the highest median excretion of ⁵¹Cr-EDTA in the study, further implicating the diarrhea-predominant phenotype with impaired intestinal barrier function; colonic permeability has been shown to correlate with stool frequency, suggesting site-specific defects in barrier function may be related to disease severity^[103]. Similar observations have been reported in the literature^[104,105]. IBS-C was not included in this review because intestinal permeability appears to be normal in this patient population^[106].

The relationship between intestinal permeability and symptoms was evaluated by Gecse *et al*^[103] (2012) who used ⁵¹Cr-EDTA as an intestinal permeability probe in patients with IBS-D^[103]. The number of stools per week was significantly correlated with permeability (Pearson $r = 0.62$; $P = 0.0057$). Interestingly, ⁵¹Cr-EDTA excretion was only elevated compared to control when measured between 5 and 24 h after ingestion, suggesting that colonic, but not small intestine, permeability may explain the study findings and indicates that site-specific permeability may be a feature of IBS-D^[103]. ⁵¹Cr-EDTA excretion was similar to patients with UC, suggesting that impaired bowel function in IBS-D may be more similar to IBD than IBS-C. It should also be noted that molecular markers of impaired intestinal barrier function help further establish the mechanistic association with IBS-D. These data indicate a strong link between intestinal barrier dysfunction, IBS-D, and disease severity. This shows that there is a good correlation between IBS-typical symptoms and the degree of increased bowel permeability. These data also indicate that the pathophysiology of IBS-D seems to differ from IBS-C.

Other measures of symptomatic disease severity, including visceral and thermal hypersensitivity to pain [visual analog score (VAS) and bowel severity (FBDSI score)], have been shown to correlate with intestinal permeability. Zhou *et al*^[104] (2009) reported that IBS-D patients with a LMR of ≥ 0.07 had significantly higher VAS intensity ratings to nociceptive and thermal pain than those IBS patients and controls with a LMR of < 0.07 ^[104]. The authors used nociceptive and thermal stimuli in areas apart from the gut because many patients with IBS frequently complain of pain in body regions somatotopically distinct from the gut. The authors hypothesized their findings may be related to sensitization of the myenteric plexus and the common spinal segments of the central nervous system, thus establishing a quantitative link between bowel permeability and pain symptoms. If true, restoring bowel permeability may also have an effect on pain.

In total, these data suggest that a therapy designed to restore intestinal barrier dysfunction may be a promising therapeutic approach in IBS-D. Similar to other gastrointestinal diseases discussed in this review, notable architectural defects in the intestinal architecture have been reported in IBS-D including decreased expression of transmembrane (e.g., occludin and claudin-1) and intercellular TJ's (e.g. ZO-1)^[107-109]. It should be noted that mood disorders are also correlated with IBS; epidemiological evidence indicates that mood disorders develop after IBS in approximately 50% of patients, implicating gut mechanisms as drivers of non-gastrointestinal symptoms. Interestingly, one study found that the LMR correlated with IBS, interference with

activities and work and retrospectively measured anxiety and depression^[98]. If true, correcting intestinal pathology (*e.g.*, intestinal barrier dysfunction) could also have a significant impact on mood disorders secondary to IBS^[93,110,111].

Alosetron (5-HT₃ receptor antagonist), rifaximin (antibacterial), and eluxadoline (mu-opioid receptor agonist) are among the few drugs with marketing authorization for IBS-D in the United States market. Alosetron was removed from the market from 2000-2002 due to safety reasons but subsequently re-introduced with a more restrictive label. The efficacy of approved agents also appears limited. For example, a meta-analysis of five rifaximin trials indicated a small improvement in global IBS symptoms when patients were treated with rifaximin (42.2%) compared to placebo (32.4%)^[112]. Other agents commonly used include antidiarrheals (*e.g.*, loperamide), bile acid sequestrants (*e.g.*, cholestyramine), antispasmodics (*e.g.*, dicyclomine), and antidepressants (tricyclic agents, *e.g.*, amitriptyline)^[113]. Nonpharmacological interventions such as probiotics and diet modification are also considered^[114,115]. The lack of robust, and well-controlled randomized trials makes it difficult to precisely quantify the efficacy and safety of all available options; however, consensus opinion and available data indicate that most patients do not achieve complete symptom relief^[113,116]. Given the newly established pathophysiologic relationship between the microbiome and interactions with certain immune cells, it seems promising to develop interventions that repair and maintain bowel permeability as next generation treatments for IBS-D.

IMMUNE CHECKPOINT INHIBITOR COLITIS

Immune checkpoint inhibitors (ICIs) are a class of monoclonal antibodies designed to interrupt critical signaling pathways between T cells and antigen-presenting cells. At least 6 approved ICIs have proven clinically effective across more than several dozen oncology indications. Despite their robust efficacy, ICIs are associated with a wide range of toxicities. The most common type of adverse events is a group of immune-mediated conditions including colitis, hepatitis, and thyroiditis, and generally appear early following treatment initiation. As these conditions resemble autoimmune diseases, this seems to suggest an abnormal or exaggerated immune response, possibly in relation to antigen exposure, such as the microbiome. Among immune-mediated diseases, gastrointestinal toxicity (ICI colitis) is the most common adverse event associated with ICI therapy that occurs usually in 6-8 wk after initiation of treatment^[117]. Diarrhea and colitis occurs in up to approximately 54% and 22% of patients treated with anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) therapy, respectively^[118]. programmed cell death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) inhibitors appear to have lower rates of diarrhea and colitis (up to 30% and 7% respectively), although the incidence of these toxicities is high in anti-CTLA4 and anti PD-1/PD-L1 combination therapy (45%), with approximately 10% of cases reported as grade 3 or higher^[117,118].

The endoscopic and histologic features of ICI-related colitis appear to resemble IBD^[117,119,120]. For example, in 39 patients with ipilimumab-induced colitis, immune infiltrate was highly prevalent: Neutrophilic infiltrate occurred in 46% of patients, lymphocytic infiltrate in 15% of patients and a mixed neutrophilic-lymphocytic infiltrate 38% of patients^[120]. Edema, erythema, erosions and ulceration are also common endoscopic features. The same study by Marthey *et al*^[120] (2016) found that 97% patients with ipilimumab-induced colitis had erythema or ulceration in the sigmoid colon or rectum and 66% had extensive colitis^[120]. The pathogenesis of ICI-related colitis, therefore, appears to relate to colonic inflammation although the precise mechanism(s) are not well characterized. Given clinicopathological similarities IBD, it is reasonable to hypothesize that impaired bowel barrier function may play a role in the development of colitis. This is supported by a retrospective study that found pre-existing IBD increases the risk of gastrointestinal adverse events following ICI therapy^[121]. Samaan *et al*^[117] (2018) proposed several barrier function-related etiopathogenic hypotheses including pre-existing intestinal dysbiosis or epithelial stress/mucositis secondary to chemotherapy^[117]. Thus, normalizing bowel barrier function may be a promising therapeutic mechanism to treat or even prevent ICI-related colitis.

NON-GASTROINTESTINAL DISEASES

While the relationship between impaired bowel barrier function and bowel pathology appears self-evident, increasing evidence has also revealed a connection between the bowel and the brain—colloquially referred to as the gut-brain axis. This axis consists of complex, bidirectional pathways relevant to normal gastrointestinal functions (*e.g.* satiation), but also to higher executive functions (*e.g.* decision making) and emotions (*e.g.* fear and stress)^[122]. Communication between the bowel and the brain is regulated at the neuronal, endocrine, and immunological level. Hence, as the lumen interfaces with the microbial environment, including signaling molecules such as quorum-sensing molecules and bile acids within the lumen, communication to the brain can reflect interaction(s) between the host and the microbiome^[123]. Substantial nonclinical and clinical evidence has revealed a well-documented connection between impaired bowel barrier function, microbial dysbiosis, and neurological diseases^[123,124]. For example, a recent nationwide longitudinal study revealed the hazard ratio of developing dementia among patients with IBD was 2.54^[125]. In Parkinson's disease, there is increasing evidence that pathogenic microbial peptides are able to access the enteric nervous system and/or systemic circulation *via* a highly permeable bowel wall, which could act as a disease trigger or driver of neuronal destruction, possibly by way of retrograde axonal and transneuronal transport of α -synuclein *via* the vagus nerve^[126]. Increased bacteria/endotoxin exposure has been shown to correlate with sigmoid mucosa α -synuclein in Parkinson's disease, consistent with findings of increased intestinal permeability in patients with Parkinson's disease^[127]. Altered intestinal permeability has been linked to other extraintestinal disease such as nonalcoholic fatty liver disease, type 1 diabetes, arthritis, and other autoimmune diseases^[128-131]. This may imply that restoring intestinal barrier function may have therapeutic benefits beyond bowel pathology alone.

CONCLUSION

Multiple genetic, environmental, and host-related risk factors play a pivotal role in the development of gastrointestinal pathology, yet the initiation of pathology coupled with the complex interplay between the microbiome and host makes the precise pathophysiology of disease difficult to assess at the individual level. Impaired intestinal barrier function appears to be a central characteristic of common gastrointestinal diseases as summarized in this review. The field of gastroenterology continues to evolve as a more precise characterization of intestinal barrier function in the context of gastrointestinal disease is uncovered. This will improve our ability to understand the complex role of intestinal barrier abnormalities and design therapeutic interventions to restore barrier function. Novel therapies may be developed to target bowel permeability which address a primary disease trigger without the side effects of traditional long-term immunosuppressive therapy.

REFERENCES

- 1 **Sender R**, Fuchs S, Milo R. Revised Estimates for the Number of Human and Bacteria Cells in the Body. *PLoS Biol* 2016; **14**: e1002533 [PMID: 27541692 DOI: 10.1371/journal.pbio.1002533]
- 2 **McCauley HA**, Guasch G. Three cheers for the goblet cell: maintaining homeostasis in mucosal epithelia. *Trends Mol Med* 2015; **21**: 492-503 [PMID: 26144290 DOI: 10.1016/j.molmed.2015.06.003]
- 3 **Kopp ZA**, Jain U, Van Limbergen J, Stadnyk AW. Do antimicrobial peptides and complement collaborate in the intestinal mucosa? *Front Immunol* 2015; **6**: 17 [PMID: 25688244 DOI: 10.3389/fimmu.2015.00017]
- 4 **McGhee JR**, Mestecky J, Dertzbaugh MT, Eldridge JH, Hirasawa M, Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. *Vaccine* 1992; **10**: 75-88 [PMID: 1539467 DOI: 10.1016/0264-410x(92)90021-b]
- 5 **van der Flier LG**, Clevers H. Stem cells, self-renewal, and differentiation in the intestinal epithelium. *Annu Rev Physiol* 2009; **71**: 241-260 [PMID: 18808327 DOI: 10.1146/annurev.physiol.010908.163145]
- 6 **Travis S**, Menzies I. Intestinal permeability: functional assessment and significance. *Clin Sci (Lond)* 1992; **82**: 471-488 [PMID: 1317756 DOI: 10.1042/cs0820471]
- 7 **Tibble JA**, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. *Gastroenterology* 2000; **119**: 15-22 [PMID: 10889150 DOI: 10.1053/gast.2000.8523]

- 8 **Bjarnason I**, MacPherson A, Hollander D. Intestinal permeability: an overview. *Gastroenterology* 1995; **108**: 1566-1581 [PMID: [7729650](#) DOI: [10.1016/0016-5085\(95\)90708-4](#)]
- 9 **Ménard S**, Cerf-Bensussan N, Heyman M. Multiple facets of intestinal permeability and epithelial handling of dietary antigens. *Mucosal Immunol* 2010; **3**: 247-259 [PMID: [20404811](#) DOI: [10.1038/mi.2010.5](#)]
- 10 **Odenwald MA**, Turner JR. Intestinal permeability defects: is it time to treat? *Clin Gastroenterol Hepatol* 2013; **11**: 1075-1083 [PMID: [23851019](#) DOI: [10.1016/j.cgh.2013.07.001](#)]
- 11 **Rao AS**, Camilleri M, Eckert DJ, Busciglio I, Burton DD, Ryks M, Wong BS, Lamsam J, Singh R, Zinsmeister AR. Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls. *Am J Physiol Gastrointest Liver Physiol* 2011; **301**: G919-G928 [PMID: [21836056](#) DOI: [10.1152/ajpgi.00168.2011](#)]
- 12 **Katouzian F**, Sblattero D, Not T, Tommasini A, Giusto E, Meiacco D, Stebel M, Marzari R, Fasano A, Ventura A. Dual sugar gut-permeability testing on blood drop in animal models. *Clin Chim Acta* 2005; **352**: 191-197 [PMID: [15653114](#) DOI: [10.1016/j.cccn.2004.09.023](#)]
- 13 **van Elburg RM**, Uil JJ, Kokke FT, Mulder AM, van de Broek WG, Mulder CJ, Heymans HS. Repeatability of the sugar-absorption test, using lactulose and mannitol, for measuring intestinal permeability for sugars. *J Pediatr Gastroenterol Nutr* 1995; **20**: 184-188 [PMID: [7714684](#) DOI: [10.1097/00005176-199502000-00008](#)]
- 14 **Bjarnason I**, O'Morain C, Levi AJ, Peters TJ. Absorption of 51chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease. *Gastroenterology* 1983; **85**: 318-322 [PMID: [6407889](#)]
- 15 **Elia M**, Behrens R, Northrop C, Wraight P, Neale G. Evaluation of mannitol, lactulose and 51Cr-labelled ethylenediaminetetra-acetate as markers of intestinal permeability in man. *Clin Sci (Lond)* 1987; **73**: 197-204 [PMID: [3115663](#) DOI: [10.1042/cs0730197](#)]
- 16 **Fritscher-Ravens A**, Schuppan D, Ellrichmann M, Schoch S, Röcken C, Brasch J, Bethge J, Böttner M, Klose J, Milla PJ. Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome. *Gastroenterology* 2014; **147**: 1012-20. e4 [PMID: [25083606](#) DOI: [10.1053/j.gastro.2014.07.046](#)]
- 17 **Kiesslich R**, Duckworth CA, Moussata D, Gloeckner A, Lim LG, Goetz M, Pritchard DM, Galle PR, Neurath MF, Watson AJ. Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease. *Gut* 2012; **61**: 1146-1153 [PMID: [22115910](#) DOI: [10.1136/gutjnl-2011-300695](#)]
- 18 **Rasmussen DN**, Karstensen JG, Riis LB, Brynkskov J, Vilmann P. Confocal Laser Endomicroscopy in Inflammatory Bowel Disease--A Systematic Review. *J Crohns Colitis* 2015; **9**: 1152-1159 [PMID: [26209861](#) DOI: [10.1093/ecco-jcc/jjv131](#)]
- 19 **de Souza HS**, Fiocchi C. Immunopathogenesis of IBD: current state of the art. *Nat Rev Gastroenterol Hepatol* 2016; **13**: 13-27 [PMID: [26627550](#) DOI: [10.1038/nrgastro.2015.186](#)]
- 20 **Shouval DS**, Rufo PA. The Role of Environmental Factors in the Pathogenesis of Inflammatory Bowel Diseases: A Review. *JAMA Pediatr* 2017; **171**: 999-1005 [PMID: [28846760](#) DOI: [10.1001/jamapediatrics.2017.2571](#)]
- 21 **Xavier RJ**, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. *Nature* 2007; **448**: 427-434 [PMID: [17653185](#) DOI: [10.1038/nature06005](#)]
- 22 **Yamamoto S**, Ma X. Role of Nod2 in the development of Crohn's disease. *Microbes Infect* 2009; **11**: 912-918 [PMID: [19573617](#) DOI: [10.1016/j.micinf.2009.06.005](#)]
- 23 **Hugot JP**, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. *Nature* 2001; **411**: 599-603 [PMID: [11385576](#) DOI: [10.1038/35079107](#)]
- 24 **Ogura Y**, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nuñez G, Cho JH. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. *Nature* 2001; **411**: 603-606 [PMID: [11385577](#) DOI: [10.1038/35079114](#)]
- 25 **Floyd DN**, Langham S, Séverac HC, Levesque BG. The economic and quality-of-life burden of Crohn's disease in Europe and the United States, 2000 to 2013: a systematic review. *Dig Dis Sci* 2015; **60**: 299-312 [PMID: [25258034](#) DOI: [10.1007/s10620-014-3368-z](#)]
- 26 **Feagan BG**, Bala M, Yan S, Olson A, Hanauer S. Unemployment and disability in patients with moderately to severely active Crohn's disease. *J Clin Gastroenterol* 2005; **39**: 390-395 [PMID: [15815207](#) DOI: [10.1097/01.mcg.0000159220.70290.41](#)]
- 27 **Mankertz J**, Schulzke JD. Altered permeability in inflammatory bowel disease: pathophysiology and clinical implications. *Curr Opin Gastroenterol* 2007; **23**: 379-383 [PMID: [17545772](#) DOI: [10.1097/MOG.0b013e32816aa392](#)]
- 28 **Hering NA**, Fromm M, Schulzke JD. Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics. *J Physiol* 2012; **590**: 1035-1044 [PMID: [22219336](#) DOI: [10.1113/jphysiol.2011.224568](#)]
- 29 **Hendrickson BA**, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. *Clin Microbiol Rev* 2002; **15**: 79-94 [PMID: [11781268](#) DOI: [10.1128/CMR.15.1.79-94.2002](#)]
- 30 **Katz KD**, Hollander D, Vadheim CM, McElree C, Delahunty T, Dadufalza VD, Krugliak P, Rotter

- Jl. Intestinal permeability in patients with Crohn's disease and their healthy relatives. *Gastroenterology* 1989; **97**: 927-931 [PMID: [2506103](#) DOI: [10.1016/0016-5085\(89\)91499-6](#)]
- 31 **Ukabam SO**, Clamp JR, Cooper BT. Abnormal small intestinal permeability to sugars in patients with Crohn's disease of the terminal ileum and colon. *Digestion* 1983; **27**: 70-74 [PMID: [6414866](#) DOI: [10.1159/000198932](#)]
 - 32 **Furuse M**, Hirase T, Itoh M, Nagafuchi A, Yonemura S, Tsukita S, Tsukita S. Occludin: a novel integral membrane protein localizing at tight junctions. *J Cell Biol* 1993; **123**: 1777-1788 [PMID: [8276896](#) DOI: [10.1083/jcb.123.6.1777](#)]
 - 33 **Tsukita S**, Furuse M, Itoh M. Multifunctional strands in tight junctions. *Nat Rev Mol Cell Biol* 2001; **2**: 285-293 [PMID: [11283726](#) DOI: [10.1038/35067088](#)]
 - 34 **Ikenouchi J**, Furuse M, Furuse K, Sasaki H, Tsukita S, Tsukita S. Tricellulin constitutes a novel barrier at tricellular contacts of epithelial cells. *J Cell Biol* 2005; **171**: 939-945 [PMID: [16365161](#) DOI: [10.1083/jcb.200510043](#)]
 - 35 **Martin-Padura I**, Lostaglio S, Schneemann M, Williams L, Romano M, Fruscella P, Panzeri C, Stoppacciaro A, Ruco L, Villa A, Simmons D, Dejana E. Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. *J Cell Biol* 1998; **142**: 117-127 [PMID: [9660867](#) DOI: [10.1083/jcb.142.1.117](#)]
 - 36 **Van Itallie C**, Rahner C, Anderson JM. Regulated expression of claudin-4 decreases paracellular conductance through a selective decrease in sodium permeability. *J Clin Invest* 2001; **107**: 1319-1327 [PMID: [11375422](#) DOI: [10.1172/JCI12464](#)]
 - 37 **Furuse M**, Hata M, Furuse K, Yoshida Y, Haratake A, Sugitani Y, Noda T, Kubo A, Tsukita S. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. *J Cell Biol* 2002; **156**: 1099-1111 [PMID: [11889141](#) DOI: [10.1083/jcb.200110122](#)]
 - 38 **Amasheh S**, Meiri N, Gitter AH, Schöneberg T, Mankertz J, Schulzke JD, Fromm M. Claudin-2 expression induces cation-selective channels in tight junctions of epithelial cells. *J Cell Sci* 2002; **115**: 4969-4976 [PMID: [12432083](#) DOI: [10.1242/jcs.00165](#)]
 - 39 **Günzel D**, Stuiver M, Kausalya PJ, Haisch L, Krug SM, Rosenthal R, Meij IC, Hunziker W, Fromm M, Müller D. Claudin-10 exists in six alternatively spliced isoforms that exhibit distinct localization and function. *J Cell Sci* 2009; **122**: 1507-1517 [PMID: [19383724](#) DOI: [10.1242/jcs.040113](#)]
 - 40 **Zeissig S**, Bürgel N, Günzel D, Richter J, Mankertz J, Wahnschaffe U, Kroesen AJ, Zeitz M, Fromm M, Schulzke JD. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. *Gut* 2007; **56**: 61-72 [PMID: [16822808](#) DOI: [10.1136/gut.2006.094375](#)]
 - 41 **Kucharzik T**, Walsh SV, Chen J, Parkos CA, Nusrat A. Neutrophil transmigration in inflammatory bowel disease is associated with differential expression of epithelial intercellular junction proteins. *Am J Pathol* 2001; **159**: 2001-2009 [PMID: [11733350](#) DOI: [10.1016/S0002-9440\(10\)63051-9](#)]
 - 42 **Das P**, Goswami P, Das TK, Nag T, Sreenivas V, Ahuja V, Panda SK, Gupta SD, Makharia GK. Comparative tight junction protein expressions in colonic Crohn's disease, ulcerative colitis, and tuberculosis: a new perspective. *Virchows Arch* 2012; **460**: 261-270 [PMID: [22297703](#) DOI: [10.1007/s00428-012-1195-1](#)]
 - 43 **Weber CR**, Nalle SC, Tretiakova M, Rubin DT, Turner JR. Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation. *Lab Invest* 2008; **88**: 1110-1120 [PMID: [18711353](#) DOI: [10.1038/labinvest.2008.78](#)]
 - 44 **Hilsden RJ**, Meddings JB, Sutherland LR. Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn's disease. *Gastroenterology* 1996; **110**: 1395-1403 [PMID: [8613043](#) DOI: [10.1053/gast.1996.v110.pm8613043](#)]
 - 45 **Munkholm P**, Langholz E, Hollander D, Thornberg K, Orholm M, Katz KD, Binder V. Intestinal permeability in patients with Crohn's disease and ulcerative colitis and their first degree relatives. *Gut* 1994; **35**: 68-72 [PMID: [8307453](#) DOI: [10.1136/gut.35.1.68](#)]
 - 46 **Buhner S**, Buning C, Genschel J, Kling K, Herrmann D, Dignass A, Kuechler I, Krueger S, Schmidt HH, Lochs H. Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation? *Gut* 2006; **55**: 342-347 [PMID: [16000642](#) DOI: [10.1136/gut.2005.065557](#)]
 - 47 **Monsén U**, Bernell O, Johansson C, Hellers G. Prevalence of inflammatory bowel disease among relatives of patients with Crohn's disease. *Scand J Gastroenterol* 1991; **26**: 302-306 [PMID: [1853152](#) DOI: [10.3109/00365529109025046](#)]
 - 48 **Marin ML**, Greenstein AJ, Geller SA, Gordon RE, Aufses AH Jr. A freeze fracture study of Crohn's disease of the terminal ileum: changes in epithelial tight junction organization. *Am J Gastroenterol* 1983; **78**: 537-547 [PMID: [6613965](#)]
 - 49 **Peeters M**, Ghooys Y, Maes B, Hiele M, Geboes K, Vantrappen G, Rutgeerts P. Increased permeability of macroscopically normal small bowel in Crohn's disease. *Dig Dis Sci* 1994; **39**: 2170-2176 [PMID: [7924738](#) DOI: [10.1007/BF02090367](#)]
 - 50 **Chang J**, Leong RW, Wasinger VC, Ip M, Yang M, Phan TG. Impaired Intestinal Permeability Contributes to Ongoing Bowel Symptoms in Patients With Inflammatory Bowel Disease and Mucosal Healing. *Gastroenterology* 2017; **153**: 723-731. e1 [PMID: [28601482](#) DOI: [10.1053/j.gastro.2017.05.056](#)]
 - 51 **Vogelsang H**. Do changes in intestinal permeability predict disease relapse in Crohn's disease?

- Inflamm Bowel Dis* 2008; **14** Suppl 2: S162-S163 [PMID: 18816766 DOI: 10.1002/ibd.20617]
- 52 **Wyatt J**, Vogelsang H, Hübl W, Waldhöer T, Lochs H. Intestinal permeability and the prediction of relapse in Crohn's disease. *Lancet* 1993; **341**: 1437-1439 [PMID: 8099141 DOI: 10.1016/0140-6736(93)90882-H]
 - 53 **D'Inca R**, Di Leo V, Corrao G, Martinez D, D'Odorico A, Mestriner C, Venturi C, Longo G, Sturniolo GC. Intestinal permeability test as a predictor of clinical course in Crohn's disease. *Am J Gastroenterol* 1999; **94**: 2956-2960 [PMID: 10520851 DOI: 10.1111/j.1572-0241.1999.01444.x]
 - 54 **Pironi L**, Miglioli M, Ruggeri E, Levorato M, Dallasta MA, Corbelli C, Nibali MG, Barbara L. Relationship between intestinal permeability to [51Cr]EDTA and inflammatory activity in asymptomatic patients with Crohn's disease. *Dig Dis Sci* 1990; **35**: 582-588 [PMID: 1691967 DOI: 10.1007/BF01540405]
 - 55 **Gerova VA**, Stoyanov SG, Katsarov DS, Svinarov DA. Increased intestinal permeability in inflammatory bowel diseases assessed by iohexol test. *World J Gastroenterol* 2011; **17**: 2211-2215 [PMID: 21633531 DOI: 10.3748/wjg.v17.i17.]
 - 56 **Turcotte JF**, Wong K, Mah SJ, Dieleman LA, Kao D, Kroeker K, Claggett B, Saltzman JR, Wine E, Fedorak RN, Liu JJ. Increased epithelial gaps in the small intestine are predictive of hospitalization and surgery in patients with inflammatory bowel disease. *Clin Transl Gastroenterol* 2012; **3**: e19 [PMID: 23238291 DOI: 10.1038/ctg.2012.13]
 - 57 **Benjamin J**, Makharia GK, Ahuja V, Kalaivani M, Joshi YK. Intestinal permeability and its association with the patient and disease characteristics in Crohn's disease. *World J Gastroenterol* 2008; **14**: 1399-1405 [PMID: 18322955 DOI: 10.3748/wjg.14.1399]
 - 58 **Hilsden RJ**, Meddings JB, Hardin J, Gall DG, Sutherland LR. Intestinal permeability and postheparin plasma diamine oxidase activity in the prediction of Crohn's disease relapse. *Inflamm Bowel Dis* 1999; **5**: 85-91 [PMID: 10338376 DOI: 10.1097/00054725-199905000-00003]
 - 59 **Arnott ID**, Kingstone K, Ghosh S. Abnormal intestinal permeability predicts relapse in inactive Crohn disease. *Scand J Gastroenterol* 2000; **35**: 1163-1169 [PMID: 11145287 DOI: 10.1080/003655200750056637]
 - 60 **Söderholm JD**, Streutker C, Yang PC, Paterson C, Singh PK, McKay DM, Sherman PM, Croitoru K, Perdue MH. Increased epithelial uptake of protein antigens in the ileum of Crohn's disease mediated by tumour necrosis factor alpha. *Gut* 2004; **53**: 1817-1824 [PMID: 15542521 DOI: 10.1136/gut.2004.041426]
 - 61 **Morson BC**. The early histological lesion of Crohn's disease. *Proc R Soc Med* 1972; **65**: 71-72 [PMID: 5015484]
 - 62 **Fujimura Y**, Kamoi R, Iida M. Pathogenesis of aphthoid ulcers in Crohn's disease: correlative findings by magnifying colonoscopy, electron microscopy, and immunohistochemistry. *Gut* 1996; **38**: 724-732 [PMID: 8707119 DOI: 10.1136/gut.38.5.724]
 - 63 **Keita AV**, Salim SY, Jiang T, Yang PC, Franzén L, Söderkvist P, Magnusson KE, Söderholm JD. Increased uptake of non-pathogenic *E. coli* via the follicle-associated epithelium in longstanding ileal Crohn's disease. *J Pathol* 2008; **215**: 135-144 [PMID: 18348161 DOI: 10.1002/path.2337]
 - 64 **Nazli A**, Wang A, Steen O, Prescott D, Lu J, Perdue MH, Söderholm JD, Sherman PM, McKay DM. Enterocyte cytoskeleton changes are crucial for enhanced translocation of nonpathogenic *Escherichia coli* across metabolically stressed gut epithelia. *Infect Immun* 2006; **74**: 192-201 [PMID: 16368973 DOI: 10.1128/IAI.74.1.192-201.2006]
 - 65 **Porras M**, Martin MT, Yang PC, Jury J, Perdue MH, Vergara P. Correlation between cyclical epithelial barrier dysfunction and bacterial translocation in the relapses of intestinal inflammation. *Inflamm Bowel Dis* 2006; **12**: 843-852 [PMID: 16954803 DOI: 10.1097/01.mib.0000231571.88806.62]
 - 66 **Na SY**, Moon W. Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease. *Gut Liver* 2019; **13**: 604-616 [PMID: 31195433 DOI: 10.5009/gnl19019]
 - 67 **Hanauer SB**, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. *Gastroenterology* 2006; **130**: 323-33; quiz 591 [PMID: 16472588 DOI: 10.1053/j.gastro.2005.11.030]
 - 68 **Schreiber S**, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ; PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn's disease. *N Engl J Med* 2007; **357**: 239-250 [PMID: 17634459 DOI: 10.1056/NEJMoa062897]
 - 69 **Sandborn WJ**, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. *Gut* 2007; **56**: 1232-1239 [PMID: 17299059 DOI: 10.1136/gut.2006.106781]
 - 70 **Hanauer SB**, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P; ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. *Lancet* 2002; **359**: 1541-1549 [PMID: 12047962 DOI: 10.1016/S0140-6736(02)08512-4]
 - 71 **Allez M**, Karmiris K, Louis E, Van Assche G, Ben-Horin S, Klein A, Van der Woude J, Baert F, Eliakim R, Katsanos K, Brynskov J, Steinwurz F, Danese S, Vermeire S, Teillaud JL, Lémann M, Chowers Y. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. *J Crohns Colitis*

- 2010; **4**: 355-366 [PMID: [21122530](#) DOI: [10.1016/j.crohns.2010.04.004](#)]
- 72 **Siegel CA**, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. *Clin Gastroenterol Hepatol* 2009; **7**: 874-881 [PMID: [19558997](#) DOI: [10.1016/j.cgh.2009.01.004](#)]
- 73 **Andersen NN**, Jess T. Risk of infections associated with biological treatment in inflammatory bowel disease. *World J Gastroenterol* 2014; **20**: 16014-16019 [PMID: [25473153](#) DOI: [10.3748/wjg.v20.i43.16014](#)]
- 74 **Toruner M**, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF, Egan LJ. Risk factors for opportunistic infections in patients with inflammatory bowel disease. *Gastroenterology* 2008; **134**: 929-936 [PMID: [18294633](#) DOI: [10.1053/j.gastro.2008.01.012](#)]
- 75 **Adegbola SO**, Sahnun K, Warusavitarne J, Hart A, Tozer P. Anti-TNF Therapy in Crohn's Disease. *Int J Mol Sci* 2018; **19** [PMID: [30065229](#) DOI: [10.3390/ijms19082244](#)]
- 76 **Boland K**, Bedrani L, Turpin W, Kabakchiev B, Stempak J, Borowski K, Nguyen G, Steinhart AH, Smith MI, Croitoru K, Silverberg MS. Persistent Diarrhea in Patients With Crohn's Disease After Mucosal Healing Is Associated With Lower Diversity of the Intestinal Microbiome and Increased Dysbiosis. *Clin Gastroenterol Hepatol* 2020 [PMID: [32220613](#) DOI: [10.1016/j.cgh.2020.03.044](#)]
- 77 **Schmitz H**, Barmeyer C, Fromm M, Runkel N, Foss HD, Bentzel CJ, Riecken EO, Schulzke JD. Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. *Gastroenterology* 1999; **116**: 301-309 [PMID: [9922310](#) DOI: [10.1016/S0016-5085\(99\)70126-5](#)]
- 78 **Gitter AH**, Wullstein F, Fromm M, Schulzke JD. Epithelial barrier defects in ulcerative colitis: characterization and quantification by electrophysiological imaging. *Gastroenterology* 2001; **121**: 1320-1328 [PMID: [11729111](#) DOI: [10.1053/gast.2001.29694](#)]
- 79 **Heller F**, Florian P, Bojarski C, Richter J, Christ M, Hillenbrand B, Mankertz J, Gitter AH, Bürgel N, Fromm M, Zeitz M, Fuss I, Strober W, Schulzke JD. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. *Gastroenterology* 2005; **129**: 550-564 [PMID: [16083712](#) DOI: [10.1016/j.gastro.2005.05.002](#)]
- 80 **Chelakkot C**, Ghim J, Ryu SH. Mechanisms regulating intestinal barrier integrity and its pathological implications. *Exp Mol Med* 2018; **50**: 103 [PMID: [30115904](#) DOI: [10.1038/s12276-018-0126-x](#)]
- 81 **Wegh CAM**, de Roos NM, Hovenier R, Meijerink J, Besseling-van der Vaart I, van Hemert S, Witteman BJM. Intestinal Permeability Measured by Urinary Sucrose Excretion Correlates with Serum Zonulin and Faecal Calprotectin Concentrations in UC Patients in Remission. *J Nutr Metab* 2019; **2019**: 2472754 [PMID: [31061734](#) DOI: [10.1155/2019/2472754](#)]
- 82 **Welcker K**, Martin A, Kölle P, Siebeck M, Gross M. Increased intestinal permeability in patients with inflammatory bowel disease. *Eur J Med Res* 2004; **9**: 456-460 [PMID: [15546811](#)]
- 83 **Büning C**, Geissler N, Prager M, Sturm A, Baumgart DC, Büttner J, Bühner S, Haas V, Lochs H. Increased small intestinal permeability in ulcerative colitis: rather genetic than environmental and a risk factor for extensive disease? *Inflamm Bowel Dis* 2012; **18**: 1932-1939 [PMID: [22344959](#) DOI: [10.1002/ibd.22909](#)]
- 84 **Fausel R**, Afzali A. Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF- α antagonists. *Ther Clin Risk Manag* 2015; **11**: 63-73 [PMID: [25609972](#) DOI: [10.2147/TCRM.S55506](#)]
- 85 **National Institute of Diabetes and Digestive and Kidney Diseases**. Definition & Facts for Irritable Bowel Syndrome. Available from: <https://www.niddk.nih.gov/health-information/digestive-diseases/irritable-bowel-syndrome/definition-facts?dkrd=hispt0257>
- 86 **Lovell RM**, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. *Clin Gastroenterol Hepatol* 2012; **10**: 712-721. e4 [PMID: [22426087](#) DOI: [10.1016/j.cgh.2012.02.029](#)]
- 87 **Paré P**, Gray J, Lam S, Balshaw R, Khorasheh S, Barbeau M, Kelly S, McBurney CR. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study. *Clin Ther* 2006; **28**: 1726-35; discussion 1710 [PMID: [17157129](#) DOI: [10.1016/j.clinthera.2006.10.010](#)]
- 88 **Mikocka-Walus A**, Turnbull D, Moulding N, Wilson I, Andrews JM, Holtmann G. Psychological comorbidity and complexity of gastrointestinal symptoms in clinically diagnosed irritable bowel syndrome patients. *J Gastroenterol Hepatol* 2008; **23**: 1137-1143 [PMID: [18070012](#) DOI: [10.1111/j.1440-1746.2007.05245.x](#)]
- 89 **Shepherd SJ**, Parker FC, Muir JG, Gibson PR. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. *Clin Gastroenterol Hepatol* 2008; **6**: 765-771 [PMID: [18456565](#) DOI: [10.1016/j.cgh.2008.02.058](#)]
- 90 **Beyder A**, Mazzone A, Strege PR, Tester DJ, Saito YA, Bernard CE, Enders FT, Ek WE, Schmidt PT, Dlugosz A, Lindberg G, Karling P, Ohlsson B, Gazouli M, Nardone G, Cuomo R, Usai-Satta P, Galeazzi F, Neri M, Portincasa P, Bellini M, Barbara G, Camilleri M, Locke GR, Talley NJ, D'Amato A, Ackerman MJ, Farrugia G. Loss-of-function of the voltage-gated sodium channel NaV1.5 (channelopathies) in patients with irritable bowel syndrome. *Gastroenterology* 2014; **146**: 1659-1668 [PMID: [24613995](#) DOI: [10.1053/j.gastro.2014.02.054](#)]
- 91 **Marshall JK**, Thabane M, Garg AX, Clark WF, Moayyedi P, Collins SM; Walkerton Health Study

- Investigators. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. *Gut* 2010; **59**: 605-611 [PMID: [20427395](#) DOI: [10.1136/gut.2009.202234](#)]
- 92 **Aziz I**, Mumtaz S, Bhola H, Chowdhury FU, Sanders DS, Ford AC. High Prevalence of Idiopathic Bile Acid Diarrhea Among Patients With Diarrhea-Predominant Irritable Bowel Syndrome Based on Rome III Criteria. *Clin Gastroenterol Hepatol* 2015; **13**: 1650-5. e2 [PMID: [25769413](#) DOI: [10.1016/j.cgh.2015.03.002](#)]
 - 93 **Sykes MA**, Blanchard EB, Lackner J, Keefer L, Krasner S. Psychopathology in irritable bowel syndrome: support for a psychophysiological model. *J Behav Med* 2003; **26**: 361-372 [PMID: [12921009](#) DOI: [10.1023/a:1024209111909](#)]
 - 94 **Kennedy PJ**, Cryan JF, Dinan TG, Clarke G. Irritable bowel syndrome: a microbiome-gut-brain axis disorder? *World J Gastroenterol* 2014; **20**: 14105-14125 [PMID: [25339800](#) DOI: [10.3748/wjg.v20.i39.14105](#)]
 - 95 **Barbara G**, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett NW, Collins SM, Corinaldesi R. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. *Gastroenterology* 2004; **126**: 693-702 [PMID: [14988823](#) DOI: [10.1053/j.gastro.2003.11.055](#)]
 - 96 **Lee H**, Park JH, Park DI, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Chae SW. Mucosal mast cell count is associated with intestinal permeability in patients with diarrhea predominant irritable bowel syndrome. *J Neurogastroenterol Motil* 2013; **19**: 244-250 [PMID: [23667756](#) DOI: [10.5056/jnm.2013.19.2.244](#)]
 - 97 **Spiller RC**, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. *Gut* 2000; **47**: 804-811 [PMID: [11076879](#) DOI: [10.1136/gut.47.6.804](#)]
 - 98 **Shulman RJ**, Jarrett ME, Cain KC, Broussard EK, Heitkemper MM. Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome. *J Gastroenterol* 2014; **49**: 1467-1476 [PMID: [24435814](#) DOI: [10.1007/s00535-013-0919-6](#)]
 - 99 **Piche T**, Barbara G, Aubert P, Bruley des Varannes S, Dainese R, Nano JL, Cremon C, Stanghellini V, De Giorgio R, Galmiche JP, Neunlist M. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. *Gut* 2009; **58**: 196-201 [PMID: [18824556](#) DOI: [10.1136/gut.2007.140806](#)]
 - 100 **Vazquez-Roque MI**, Camilleri M, Smyrk T, Murray JA, O'Neill J, Carlson P, Lamsam J, Eckert D, Janzow D, Burton D, Ryks M, Rhoten D, Zinsmeister AR. Association of HLA-DQ gene with bowel transit, barrier function, and inflammation in irritable bowel syndrome with diarrhea. *Am J Physiol Gastrointest Liver Physiol* 2012; **303**: G1262-G1269 [PMID: [23042942](#) DOI: [10.1152/ajpgi.00294.2012](#)]
 - 101 **Shanahan F**, Quigley EM. Manipulation of the microbiota for treatment of IBS and IBD-challenges and controversies. *Gastroenterology* 2014; **146**: 1554-1563 [PMID: [24486051](#) DOI: [10.1053/j.gastro.2014.01.050](#)]
 - 102 **Dunlop SP**, Hebden J, Campbell E, Naesdal J, Olbe L, Perkins AC, Spiller RC. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. *Am J Gastroenterol* 2006; **101**: 1288-1294 [PMID: [16771951](#) DOI: [10.1111/j.1572-0241.2006.00672.x](#)]
 - 103 **Gecse K**, Róka R, Séra T, Rosztóczy A, Annaházi A, Izbéki F, Nagy F, Molnár T, Szepes Z, Pávics L, Bueno L, Wittmann T. Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis. *Digestion* 2012; **85**: 40-46 [PMID: [22179430](#) DOI: [10.1159/000333083](#)]
 - 104 **Zhou Q**, Zhang B, Verne GN. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. *Pain* 2009; **146**: 41-46 [PMID: [19595511](#) DOI: [10.1016/j.pain.2009.06.017](#)]
 - 105 **Mujagic Z**, Ludidi S, Keszthelyi D, Hesselink MA, Kruijmel JW, Lenaerts K, Hanssen NM, Conchillo JM, Jonkers DM, Masclee AA. Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders. *Aliment Pharmacol Ther* 2014; **40**: 288-297 [PMID: [24943095](#) DOI: [10.1111/apt.12829](#)]
 - 106 **Peters SA**, Edogawa S, Sundt WJ, Dyer RB, Dalenberg DA, Mazzone A, Singh RJ, Moses N, Smyrk TC, Weber C, Linden DR, MacNaughton WK, Turner JR, Camilleri M, Katza DA, Farrugia G, Grover M. Constipation-Predominant Irritable Bowel Syndrome Females Have Normal Colonic Barrier and Secretory Function. *Am J Gastroenterol* 2017; **112**: 913-923 [PMID: [28323272](#) DOI: [10.1038/ajg.2017.48](#)]
 - 107 **Zhao DY**, Qi QQ, Long X, Li X, Chen FX, Yu YB, Zuo XL. Ultrastructure of intestinal mucosa in diarrhea-predominant irritable bowel syndrome. *Physiol Int* 2019; **106**: 225-235 [PMID: [31560236](#) DOI: [10.1556/2060.106.2019.20](#)]
 - 108 **Bertiaux-Vandaële N**, Youmba SB, Belmonte L, Lecleire S, Antonietti M, Gourcerol G, Leroi AM, Déchelotte P, Ménard JF, Ducrotté P, Coëffier M. The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype. *Am J Gastroenterol* 2011; **106**: 2165-2173 [PMID: [22008894](#) DOI: [10.1038/ajg.2011.257](#)]
 - 109 **Bertrand J**, Ghouzali I, Guérin C, Bôle-Feysot C, Gouteux M, Déchelotte P, Ducrotté P, Coëffier M. Glutamine Restores Tight Junction Protein Claudin-1 Expression in Colonic Mucosa of Patients With Diarrhea-Predominant Irritable Bowel Syndrome. *JPEN J Parenter Enteral Nutr* 2016; **40**:

- 1170-1176 [PMID: [25972430](#) DOI: [10.1177/0148607115587330](#)]
- 110 **Koloski NA**, Jones M, Talley NJ. Evidence that independent gut-to-brain and brain-to-gut pathways operate in the irritable bowel syndrome and functional dyspepsia: a 1-year population-based prospective study. *Aliment Pharmacol Ther* 2016; **44**: 592-600 [PMID: [27444264](#) DOI: [10.1111/apt.13738](#)]
 - 111 **Koloski NA**, Jones M, Kalantar J, Weltman M, Zaguirre J, Talley NJ. The brain-gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. *Gut* 2012; **61**: 1284-1290 [PMID: [22234979](#) DOI: [10.1136/gutjnl-2011-300474](#)]
 - 112 **Menees SB**, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. *Am J Gastroenterol* 2012; **107**: 28-35; quiz 36 [PMID: [22045120](#) DOI: [10.1038/ajg.2011.355](#)]
 - 113 **Lacy BE**. Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome. *Int J Gen Med* 2016; **9**: 7-17 [PMID: [26929659](#) DOI: [10.2147/IJGM.S93698](#)]
 - 114 **Aragon G**, Graham DB, Borum M, Doman DB. Probiotic therapy for irritable bowel syndrome. *Gastroenterol Hepatol (N Y)* 2010; **6**: 39-44 [PMID: [20567539](#)]
 - 115 **Didari T**, Mozaffari S, Nikfar S, Abdollahi M. Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. *World J Gastroenterol* 2015; **21**: 3072-3084 [PMID: [25780308](#) DOI: [10.3748/wjg.v21.i10.3072](#)]
 - 116 **American College of Gastroenterology Task Force on Irritable Bowel Syndrome**, Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, Spiegel BM, Talley NJ, Quigley EM. An evidence-based position statement on the management of irritable bowel syndrome. *Am J Gastroenterol* 2009; **104** Suppl 1: S1-35 [PMID: [19521341](#) DOI: [10.1038/ajg.2008.122](#)]
 - 117 **Samaan MA**, Pavlidis P, Papa S, Powell N, Irving PM. Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. *Nat Rev Gastroenterol Hepatol* 2018; **15**: 222-234 [PMID: [29512649](#) DOI: [10.1038/nrgastro.2018.14](#)]
 - 118 **Belum VR**, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, Motzer RJ, Wu S, Busam KJ, Wolchok JD, Lacouture ME. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. *Eur J Cancer* 2016; **60**: 12-25 [PMID: [27043866](#) DOI: [10.1016/j.ejca.2016.02.010](#)]
 - 119 **Beck KE**, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. *J Clin Oncol* 2006; **24**: 2283-2289 [PMID: [16710025](#) DOI: [10.1200/JCO.2005.04.5716](#)]
 - 120 **Marthey L**, Mateus C, Mussini C, Nachury M, Nancey S, Grange F, Zallot C, Peyrin-Biroulet L, Rahier JF, Bourdier de Beauregard M, Mortier L, Coutzac C, Soularue E, Lanoy E, Kapel N, Planchard D, Chaput N, Robert C, Carbonnel F. Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. *J Crohns Colitis* 2016; **10**: 395-401 [PMID: [26783344](#) DOI: [10.1093/ecco-jcc/jjv227](#)]
 - 121 **Abu-Sbeih H**, Faleck DM, Ricciuti B, Mendelsohn RB, Naqash AR, Cohen JV, Sellers MC, Balaji A, Ben-Betzalel G, Hajir I, Zhang J, Awad MM, Leonardi GC, Johnson DB, Pinato DJ, Owen DH, Weiss SA, Lamberti G, Lythgoe MP, Manuzzi L, Arnold C, Qiao W, Naidoo J, Markel G, Powell N, Yeung SJ, Sharon E, Dougan M, Wang Y. Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. *J Clin Oncol* 2020; **38**: 576-583 [PMID: [31800340](#) DOI: [10.1200/JCO.19.01674](#)]
 - 122 **Mayer EA**. Gut feelings: the emerging biology of gut-brain communication. *Nat Rev Neurosci* 2011; **12**: 453-466 [PMID: [21750565](#) DOI: [10.1038/nrn3071](#)]
 - 123 **Mayer EA**, Tillisch K, Gupta A. Gut/brain axis and the microbiota. *J Clin Invest* 2015; **125**: 926-938 [PMID: [25689247](#) DOI: [10.1172/JCI76304](#)]
 - 124 **Grenham S**, Clarke G, Cryan JF, Dinan TG. Brain-gut-microbe communication in health and disease. *Front Physiol* 2011; **2**: 94 [PMID: [22162969](#) DOI: [10.3389/fphys.2011.00094](#)]
 - 125 **Zhang B**, Wang HE, Bai YM, Tsai SJ, Su TP, Chen TJ, Wang YP, Chen MH. Inflammatory bowel disease is associated with higher dementia risk: a nationwide longitudinal study. *Gut* 2020 [PMID: [32576641](#) DOI: [10.1136/gutjnl-2020-320789](#)]
 - 126 **Braak H**, Rüb U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. *J Neural Transm (Vienna)* 2003; **110**: 517-536 [PMID: [12721813](#) DOI: [10.1007/s00702-002-0808-2](#)]
 - 127 **Forsyth CB**, Shannon KM, Kordower JH, Voigt RM, Shaikh M, Jaglin JA, Estes JD, Dodiya HB, Keshavarzian A. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. *PLoS One* 2011; **6**: e28032 [PMID: [22145021](#) DOI: [10.1371/journal.pone.0028032](#)]
 - 128 **Miele L**, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, Mascianà R, Forgione A, Gabrieli ML, Perotti G, Vecchio FM, Rapaccini G, Gasbarrini G, Day CP, Grieco A. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. *Hepatology* 2009; **49**: 1877-1887 [PMID: [19291785](#) DOI: [10.1002/hep.22848](#)]
 - 129 **Li X**, Atkinson MA. The role for gut permeability in the pathogenesis of type 1 diabetes--a solid or leaky concept? *Pediatr Diabetes* 2015; **16**: 485-492 [PMID: [26269193](#) DOI: [10.1111/pedi.12305](#)]
 - 130 **Tajik N**, Frech M, Schulz O, Schälter F, Lucas S, Azizov V, Dürholz K, Steffen F, Omata Y, Rings A, Bertog M, Rizzo A, Iljazovic A, Basic M, Kleyer A, Culemann S, Krönke G, Luo Y, Überla K, Gaip US, Frey B, Strowig T, Sarter K, Bischoff SC, Wirtz S, Cañete JD, Ciccio F, Schett G, Zaiss

- MM. Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis. *Nat Commun* 2020; **11**: 1995 [PMID: [32332732](#) DOI: [10.1038/s41467-020-15831-7](#)]
- 131 **Mu Q**, Kirby J, Reilly CM, Luo XM. Leaky Gut As a Danger Signal for Autoimmune Diseases. *Front Immunol* 2017; **8**: 598 [PMID: [28588585](#) DOI: [10.3389/fimmu.2017.00598](#)]
- 132 **Ma TY**, Hollander D, Krugliak P, Katz K. PEG 400, a hydrophilic molecular probe for measuring intestinal permeability. *Gastroenterology* 1990; **98**: 39-46 [PMID: [2293598](#) DOI: [10.1016/0016-5085\(90\)91288-H](#)]
- 133 **Anderson AD**, Jain PK, Fleming S, Poon P, Mitchell CJ, MacFie J. Evaluation of a triple sugar test of colonic permeability in humans. *Acta Physiol Scand* 2004; **182**: 171-177 [PMID: [15450113](#) DOI: [10.1111/j.1365-201X.2004.01347.x](#)]
- 134 **Meddings JB**, Sutherland LR, Byles NI, Wallace JL. Sucrose: a novel permeability marker for gastroduodenal disease. *Gastroenterology* 1993; **104**: 1619-1626 [PMID: [8500718](#) DOI: [10.1016/0016-5085\(93\)90637-R](#)]
- 135 **Secondulfo M**, de Magistris L, Fiandra R, Caserta L, Belletta M, Tartaglione MT, Riegler G, Biagi F, Corazza GR, Carratù R. Intestinal permeability in Crohn's disease patients and their first degree relatives. *Dig Liver Dis* 2001; **33**: 680-685 [PMID: [11785714](#) DOI: [10.1016/S1590-8658\(01\)80045-1](#)]
- 136 **Jenkins RT**, Jones DB, Goodacre RL, Collins SM, Coates G, Hunt RH, Bienenstock J. Reversibility of increased intestinal permeability to 51Cr-EDTA in patients with gastrointestinal inflammatory diseases. *Am J Gastroenterol* 1987; **82**: 1159-1164 [PMID: [3118697](#)]
- 137 **Zhou Q**, Souba WW, Croce CM, Verne GN. MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome. *Gut* 2010; **59**: 775-784 [PMID: [19951903](#) DOI: [10.1136/gut.2009.181834](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

